Free Trial

PureTech Health (LON:PRTC) Share Price Passes Below Fifty Day Moving Average - Here's Why

PureTech Health logo with Medical background

PureTech Health plc (LON:PRTC - Get Free Report) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 131.57 ($1.77) and traded as low as GBX 127.40 ($1.72). PureTech Health shares last traded at GBX 127.40 ($1.72), with a volume of 48,707 shares changing hands.

PureTech Health Price Performance

The stock's 50 day moving average price is GBX 131.80 and its two-hundred day moving average price is GBX 135.27. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The firm has a market capitalization of £391.10 million, a price-to-earnings ratio of -5.34 and a beta of 1.02.

Insider Buying and Selling at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction dated Thursday, July 3rd. The shares were bought at an average cost of GBX 1 ($0.01) per share, with a total value of £1,677.39 ($2,262.77). Insiders own 15.93% of the company's stock.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

See Also

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines